Sinil Pharmaceutical (A012790) Stock Overview
Manufactures and sells pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A012790 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sinil Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,420.00 |
| 52 Week High | ₩6,930.00 |
| 52 Week Low | ₩5,340.00 |
| Beta | 0.58 |
| 1 Month Change | -13.69% |
| 3 Month Change | -14.24% |
| 1 Year Change | -19.23% |
| 3 Year Change | -33.82% |
| 5 Year Change | -59.54% |
| Change since IPO | 401.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| A012790 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -4.6% | -4.7% | 6.7% |
| 1Y | -19.2% | 17.3% | 195.0% |
Return vs Industry: A012790 underperformed the KR Pharmaceuticals industry which returned 17.3% over the past year.
Return vs Market: A012790 underperformed the KR Market which returned 195% over the past year.
Price Volatility
| A012790 volatility | |
|---|---|
| A012790 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A012790 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A012790's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Mi-Keun Jung | www.sinilpharm.com |
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In addition, it is involved in the real estate rental services.
Sinil Pharmaceutical Co., Ltd. Fundamentals Summary
| A012790 fundamental statistics | |
|---|---|
| Market cap | ₩61.66b |
| Earnings (TTM) | ₩6.95b |
| Revenue (TTM) | ₩82.18b |
Is A012790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A012790 income statement (TTM) | |
|---|---|
| Revenue | ₩82.18b |
| Cost of Revenue | ₩46.99b |
| Gross Profit | ₩35.20b |
| Other Expenses | ₩28.25b |
| Earnings | ₩6.95b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 611.05 |
| Gross Margin | 42.83% |
| Net Profit Margin | 8.46% |
| Debt/Equity Ratio | 0% |
How did A012790 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/30 23:38 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinil Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.